PS
PACB icon

Principal Securities’s Pacific Biosciences PACB Stock Holding History

Principal Securities’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-481
Closed -$616 – 2856
2025
Q3 		$616 Sell
481
-238
-33% -$322 ﹤0.01% 3503
2025
Q2 		$892 Hold
719
– – ﹤0.01% 3369
2025
Q1 		$1.32K Hold
719
– – ﹤0.01% 3147
2024
Q4 		$1.32K Hold
719
– – ﹤0.01% 3141
2024
Q3 		$1.22K Buy
719
+350
+95% +$575 ﹤0.01% 3092
2024
Q2 		$506 Sell
369
-150
-29% -$303 ﹤0.01% 3201
2024
Q1 		$1.95K Buy
519
+45
+9% +$263 ﹤0.01% 2883
2023
Q4 		$4.65K Buy
+474
New +$3.88K ﹤0.01% 2558

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Securities's PACB Position: Q4 2025 in Review

Principal Securities sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 481 shares — an estimated $616 sold.

Principal Securities first reported a position in PACB in Q4 2023 and held it in 8 quarters. The position peaked at $4.65K in Q4 2023. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • Principal Securities reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 481 Pacific Biosciences shares in Q4 2025, an estimated $616.
  • Principal Securities first reported a position in Pacific Biosciences in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Pacific Biosciences position peaked at $4.65K in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.